Difference between revisions of "Plicamycin (Mithracin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp") |
||
| (16 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Antibiotic oncologic, intercalates DNA base pairs, and inhibits DNA and RNA synthesis. Has been used for hypercalcemia; lowers serum calcium levels independent of cytotoxic activity by blocking parathyroid hormone action on osteoclasts.<ref name="insert">[http://www.bccancer.bc.ca/NR/rdonlyres/4282ACD1-7309-40E3-B7DA-BB54265E0D63/19525/Plicamycinmonograph_3Nov06.pdf Plicamycin (Mithracin) package insert]</ref><ref>[ | + | Class/mechanism: Antibiotic oncologic, intercalates DNA base pairs, and inhibits DNA and RNA synthesis. Has been used for hypercalcemia; lowers serum calcium levels independent of cytotoxic activity by blocking parathyroid hormone action on osteoclasts.<ref name="insert">[http://www.bccancer.bc.ca/NR/rdonlyres/4282ACD1-7309-40E3-B7DA-BB54265E0D63/19525/Plicamycinmonograph_3Nov06.pdf Plicamycin (Mithracin) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/plicamycin.pdf Plicamycin (Mithracin) package insert (locally hosted backup)]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]]/[[vesicant]] | <br>Extravasation: [[irritant]]/[[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/plicamycin-patient-drug-information Plicamycin (Mithracin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/plicamycin-patient-drug-information Plicamycin (Mithracin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/plicamycin-patient-drug-information Plicamycin (Mithracin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/plicamycin-patient-drug-information Plicamycin (Mithracin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Chronic myeloid leukemia - historical|Chronic myeloid leukemia]] | ||
| + | *[[Testicular cancer - historical|Testicular cancer]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1970: Original approval for an unclear indication. ''(No supporting studies are cited)'' | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Generic name:''' mithramycin | ||
| + | *'''Brand name:''' Mithracin | ||
==References== | ==References== | ||
| Line 13: | Line 24: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | [[Category: | + | [[Category:Intravenous medications]] |
| − | [[Category:Irritant | + | [[Category:Irritant]] |
| − | [[Category:Vesicant | + | [[Category:Vesicant]] |
| − | [[Category:DNA synthesis inhibitors]] | + | [[Category:Human DNA synthesis inhibitors]] |
| − | [[Category: | + | [[Category:Chronic myeloid leukemia medications (historic)]] |
| + | [[Category:Testicular cancer medications (historic)]] | ||
| + | [[Category:FDA approved in 1970]] | ||
| + | [[Category:Discontinued drugs]] | ||
Latest revision as of 12:03, 29 June 2024
General information
Class/mechanism: Antibiotic oncologic, intercalates DNA base pairs, and inhibits DNA and RNA synthesis. Has been used for hypercalcemia; lowers serum calcium levels independent of cytotoxic activity by blocking parathyroid hormone action on osteoclasts.[1][2]
Route: IV
Extravasation: irritant/vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Diseases for which it was used
History of changes in FDA indication
- 1970: Original approval for an unclear indication. (No supporting studies are cited)
Also known as
- Generic name: mithramycin
- Brand name: Mithracin